Velcade

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

... multiple myeloma who have not previously received velcade and have received at least one prior therapy. DOX...iple myeloma study, 25 patients (8 percent) in the velcade for Injection arm and 42 patients (13 percent) in the velcade plus DOXIL arm experienced left ventricular ejecti...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...oma II-39 Takeda Gains FDA Approval to Promote velcade II-40 Health Canada Approves velcade II-40 Genzyme Receives FDA Certification for M...era Therapeutics Acquires LymphoSign Inc II-49 velcade Gains Subsidy II-50 Inex Pharmaceuticals Spins...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

...any today announced that 100 data presentations on velcade research will be featured at the Fifth Internation... updated results on overall survival and safety of velcade based therapies in patients with relapsed or previ.... "Data presented further establish the benefit of velcade based treatment options, and we applaud these inve...

USC study finds that green tea blocks benefits of cancer drug

... EGCG destroys any anticancer activity of the drug velcade in tumor-bearing mice, will be published in a futu...that GTE or EGCG blocked the therapeutic action of velcade was completely unexpected," says lead author Axel ...cts of Velcade, and that a combination of GTE with velcade (or EGCG with Velcade) would turn out to be a supe...

Johnson & Johnson Reports 2008 Third-Quarter Results:

...% WW 728 613 18.8% 17.6% 1.2% velcade ------- US 1 2 -50.0% -50.0% ...0.0% WW 2,051 1,801 13.9% 12.1% 1.8% velcade ------- US 4 5 -20.0% -20.0% ...

Combination Therapy Helps to Combat Myeloma

... Adding velcade to standard drug therapy prolonged survival, study...therapy lived longer and better by adding the drug velcade to standard treatment, a new study found. The f... The two-year survival rate among patients taking velcade with melphalan and prednisone was 82 percent, comp...

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

...e U.S. Food and Drug Administration (FDA) approved velcade for patients with previously untreated multiple my...eliver a significant increase in overall survival. velcade treatment also is available for multiple myeloma p...al prophylaxis was recommended for patients on the velcade study arm. Time-to-progression (TTP) was the prima...

Blood Cancer Drug Shows Promise Against Lupus

... Experiments with mice found velcade reduced dangerous autoantibodies SUNDAY, June 8 (HealthDay News... chronic autoimmune disease lupus, German researchers report. The drug, velcade (bortezomib), which is a proteasome inhibitor, worked against the disease a...

Millennium Expands IBD Franchise with Addition of New Development Candidate

...ive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of velcade and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to condu...

Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients

...edical Officer, Millennium. "We are confident that velcade will be a key component of the standard of care in...as predictable and manageable. Patients received velcade at 1.3 mg/m2 (n=54) or 1.0 mg/m2 (n=6) twice weekl...and over 45,000 deaths annually. About VELCADE velcade is being co-developed by Millennium Pharmaceutical...

Velcade in Medical Technology

Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results

EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma. LOS ANGELES, Feb. 11 /PRNewswire/ -- Quadramet (153 Samarium-lexidronam) is a radioactive medication that targets t...

Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection

- Findings Published in Blood Highlight Millennium Leadership in Personalized Medicine and Could Strengthen the Role of VELCADE as Foundation of Therapy in Broad Range of Multiple Myeloma Patients - CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-FirstCall/ -- Findings published in the April 15th iss...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential for new option to improve convenience for patients - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the presentation of positive data for VELCADE, the market-leading therapy for patient...

Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said that d...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... multiple myeloma who have not previously received velcade and have received at least one prior therapy. DOX... myeloma study, 25 patients (8%) in the velcade for Injection arm and 42 patients (13%) in the velcade plus DOXIL arm experienced left ventric...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

...iven VELCADE, melphalan and prednisone (VcMP). The velcade combination demonstrated consistent efficacy in al...a from the VISTA study showed that the addition of velcade to melphalan and prednisone continued to demonstra... "This update demonstrates that the use of velcade upfront delivers an improvement in overall surviva...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

...ti-center, randomized Phase III clinical trials of velcade based combinations for the induction treatment of ...survival (PFS) was observed in one study comparing velcade and dexamethasone (VcD) with vincristine, adriamyc...nslates to improved progression-free survival when velcade regimens are used in conjunction with high dose th...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

...uilds on positive results from previous studies of velcade based combinations in this setting. The presentati...tients." During Phase I, patients received velcade at 1.3 mg/m(2) on days 1, 4, 8 and 11 on a 21-day ...or up to eight 21-day cycles. This was followed by velcade at 1.3 mg/m(2) on days 1, 8, 15 and 22 for four 42...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

...O ) "These data demonstrate that treatment with velcade plus melphalan and prednisone leads to a survival ...ts, the U.S. Food and Drug Administration approved velcade for patients with previously untreated multiple my...ultiple myeloma patients now can benefit from this velcade based therapy as have patients in the relapsed and...

Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer

.... -- The Company expects to have initial data available in the third quarter of 2008 from a randomized Phase 2 trial of HGS-ETR1 in combination with velcade (bortezomib) in advanced multiple myeloma. Patients in the multiple myeloma study will continue on treatment until the progression of disease. These...

More>>

Velcade in Biological News

Researchers wake up viruses inside tumors to image and then destroy cancers

... market ?one of which is the multiple myeloma drug velcade ?to light up tumor viruses on a gamma camera. The ...-Barr viral infection. Tumors glowed in mice given velcade followed by an injection of FIAU, but not in mice ... Epstein-Barr virus also did not respond to either velcade or FIAU, according to researchers. "Velcade w...

Velcade in Biological Technology

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... multiple myeloma who have not previously received velcade and have received at least one prior therapy. DOX...ed multiple myeloma study, 25 patients (8%) in the velcade for Injection arm and 42 patients (13%) in the velcade plus DOXIL arm experienced left ventricular ejecti...

Human Genome Sciences Advances Oncology Portfolio

... cancers: -- HGS has completed the enrollment and initial dosing of 105 patients in a randomized Phase 2 trial of HGS-ETR1 in combination with velcade (bortezomib) in advanced multiple myeloma, and expects to have data available in the third quarter of 2008. -- In December 2007, HGS initiat...

Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion

...rotein homeostasis; -- Capitalize on Millennium proven drug development capabilities and regulatory expertise, which allowed the Company to bring velcade to market rapidly; -- Leverage the Millennium experienced sales force, established relationships with oncology thought leaders and highly-reg...

Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales

... further sales acceleration should the FDA approve velcade for, and after we begin to promote for use in pati...igible to benefit from VELCADE." About VELCADE velcade is being co-developed by Millennium Pharmaceutical...Millennium is responsible for commercialization of velcade in the U.S. and Janssen-Cilag is responsible for c...

Millennium Over-Delivers on 2007 Goals and Financial Guidance

...765 million in 2007 - - velcade granted priority review by FDA in newly diagnosed ... result of: -- A 20 percent increase in velcade U.S. net sales to $265.2 million; and ... million, as a result of strong growth in velcade sales outside of the U.S. This growth led...

Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results

... 2007- - sNDA submitted for velcade expansion into front-line multiple myeloma - - MLN... will focus on three strategic drivers. Maximize velcade Opportunity Millennium, along with its co-develo... L.L.C. (J&JPRD), continues to drive the growth of velcade worldwide. In 2007, U.S. net sales grew 20 percent...

Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection

...r achieving a material sales milestone in 2007 for velcade outside the U.S. Milestone payments are recorded i...ch and its affiliate, Janssen-Cilag, commercialize velcade outside of the U.S. and Millennium receives royalt...and over 45,000 deaths annually. About VELCADE velcade is being co-developed by Millennium Pharmaceutical...

Biotech Survives Market Turbulence in November

... Millennium Pharmaceuticals Inc. (up 25%). At one point shares of Millennium hit a new annual high amid a sharp rise in revenues for their cancer drug velcade and upcoming Phase III trial data in multiple myeloma. Millennium's share value did take a slight hit after reporting that it was dropping development...

Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales

... -- velcade third-quarter U.S. net sales increased 32% year-ov...ember 2007 -- -- velcade listed in national compendia for use in newly diag...ple myeloma -- -- velcade label broadened by FDA providing further different...